DKCM
NBIX icon

Davidson Kempner Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Davidson Kempner Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-80,200
Closed -$6.22M – 190
2017
Q4 		$6.22M Sell
80,200
-39,100
-33% -$2.67M 0.08% 124
2017
Q3 		$7.31M Buy
119,300
+40,200
+51% +$2.12M 0.1% 129
2017
Q2 		$3.64M Buy
+79,100
New +$3.84M 0.05% 138

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Davidson Kempner Capital Management's NBIX Position: Q1 2018 in Review

Davidson Kempner Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 80,200 shares — an estimated $6.22M sold.

Davidson Kempner Capital Management first reported a position in NBIX in Q2 2017 and held it in 3 quarters. The position peaked at $7.31M in Q3 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

  • Davidson Kempner Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 80,200 Neurocrine Biosciences shares in Q1 2018, an estimated $6.22M.
  • Davidson Kempner Capital Management first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 3 quarters.
  • Davidson Kempner Capital Management's Neurocrine Biosciences position peaked at $7.31M in Q3 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2018, filed 15 May 2018.